Real-world outcomes with palbociclib, ribociclib, and abemaciclib plus endocrine therapy in HR+/HER2− advanced breast cancer: A multicenter retrospective study

Background: Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy (ET) are the standard first- and second-line treatments for hormone receptor-positive (HR+), HER2-negative (HER2−) advanced breast cancer (ABC). Real-world data (RWD) may inform the optimal use of these agen...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Renata Duchnowska, Katarzyna Soter, Katarzyna Pogoda, Jolanta Smok-Kalwat, Aleksandra Grela-Wojewoda, Karolina Winsko-Szczęsnowicz, Agnieszka Kowalewska-Felczak, Marek Szwiec, Iwona Danielewicz, Joanna Streb, Tomasz Lewandowski, Bartosz Szymanowski, Joanna Kiszka, Barbara Radecka, Ewa Kalinka, Bartosz K. Sobocki, Maria Litwiniuk, Aleksandra Łacko, Anna Bałata, Justyna Żubrowska, Marek Ziobro, Bogumiła Czartoryska-Arłukowicz, Rodryg Ramlau, Paulina Myśliwiec, Paulina Lipiec, Michał Jurczyk, Grzegorz Kade, Magdalena Łobaza, Joanna Hudała-Klecha, Magdalena Szymanik-Resko, Ewa Kustra, Anna Koriat-Błońska, Bartłomiej Tomasik, Michał Bieńkowski, Jacek Jassem
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Elsevier 2026-02-01
coleção:	Breast
Assuntos:	HR+/HER2− advanced breast cancer Real-world data Cyclin-dependent kinase 4/6 inhibitors Palbociclib Ribociclib Abemaciclib
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S0960977625008847
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!